Talecris agrees to $3.4 bln bid by Spain’s Grifols – MarketWatch
By Dr. Matthew Watson
 RTT News | Talecris agrees to $3.4 bln bid by Spain's Grifols MarketWatch TEL AVIV (MarketWatch) -- Talecris Biotherapeutics (NASDAQ:TLCR) , the Research Triangle Park, NC, biotechnology firm, definitively agreed to be acquired by ... Grifols To Pay $3.4 Bln In Cash, Shares For TalecrisWall Street Journal WSJ: Spain's Grifols In Talks To Buy Talecris Biotherapeutics For About $3 Bln ...Daily Markets Grifols to Acquire Talecris Biotherapeutics Creating a World Leading Provider ...PR Newswire (press release) |
Uncategorized
Comments Off on Talecris agrees to $3.4 bln bid by Spain’s Grifols – MarketWatch |
June 7th, 2010
This author published 5472 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research